Nanophere's Product Sales Offset Lost Contracts, Lower Grant Revenue in Q2 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere reported after the close of the market on Tuesday that its second-quarter revenues declined around 2 percent year over year, as a 60 percent increase in product sales largely made up for its loss of grant and contract revenue.

The Northbrook, Ill.-based molecular diagnostics firm brought in total revenues of $509,000 for the three-month period ended June 30, down from $517,000 for Q2 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.